Steven D. Maslowski

Specialty / focus areas. Maslowski is a trial-focused patent litigator whose practice centers on life sciences — biologics and monoclonal antibodies, small-molecule drugs, ANDA/Hatch-Waxman disputes, and medical devices — with additional experience in trade secrets, ITC Section 337 investigations, and arbitrations (Akin Gump profile; IPWatchdog, Feb. 1, 2018). His single tracked matter, Voxer, Inc. v. Amazon.com, Inc. (D. Del., filed July 2025), is an outlier in technology area: Voxer, an operating company, asserts five telecommunications/video-streaming patents against Amazon and Twitch — the same network-reception patents that produced a $206M verdict against Meta in 2023 (later vacated after settlement) (Law360; Reuters).

Side preference. The tracked data shows one plaintiff-side appearance (1-0) for Voxer, a company enforcing its own patents rather than an NPE. His verifiable practice, however, skews heavily toward defending operating companies: Boston Scientific, 3M, Merck, Bristol-Myers Squibb, Janssen, Ethicon, and Johnson & Johnson are recurring clients (Akin Gump profile; PlainSite docket lists). He has also prosecuted infringement claims for operating companies (Centocor, BMS), so he works both sides but is best known as defense counsel for life sciences companies.

Firm context. Maslowski is a partner in Akin Gump's Philadelphia office and has headed the firm's IP practice since 2018 (named co-head, then sole head) (IPWatchdog). Available sources show his entire career at Akin Gump; no prior-firm history surfaced.

Notable cases / outcomes. Verified highlights include the $1.67B jury verdict for Centocor Ortho Biotech and NYU against Abbott over Humira (2009; reported at the time as the largest U.S. patent verdict — Law360/2010 "Rising Star" profile); a $20M willful-infringement verdict for Boston Scientific against Nevro in a spinal cord stimulation dispute; the BMS/Ono/Honjo immuno-oncology litigation against Merck, settled with a $625M initial payment plus royalties through 2026; invalidation of Abbott's Stelara patents, affirmed by the Federal Circuit; and complete dismissal of AptarGroup's suit against Merck/3M after parallel IPRs invalidated the asserted patents. He has appeared regularly before the PTAB in IPR proceedings, including parallel IPRs in the Boston Scientific/Nevro and AptarGroup matters (Akin Gump profile; PTAB filings).

Bar / education. B.S., Pennsylvania State University (1995); J.D., George Washington University Law School, with honors (1999); admitted in Pennsylvania (1999), registered with the USPTO (Reg. No. 46,905), and admitted to the Federal Circuit and U.S. Supreme Court (Martindale-Hubbell).